• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Novo Nordisk

320.60 DKK+0.09 %24.7. klo 18.09
1,055 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.09 %
+4.18 %
+29.96 %
-20.12 %
-1.43 %
-27.60 %
-42.19 %
+12.31 %
+25,651.00 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.43T DKK
Turnover
959.36M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
The market is currently paying far too much attention to who has the best percentages in clinical trials. In 5 years, it won’t matter whether the figure is 18%, 23%, or 28%. For the consumer, price will be the deciding factor and other things will be secondary. And since patents ...
6/6/2026, 7:27 PM
by JNivala
65
Boostia Wegovylle uuden myyntiluvan muodossa. First GLP-1 pill approved in the European Union for the treatment of obesity and overweight Novo Nordisk News Details
7/15/2026, 5:40 PM
by Keepitcoming
30
Yep, I’ve been pondering the same thing—why hasn’t this price collapse affected Eli Lilly’s valuation multiples? To a layman’s eye, the new drugs don’t seem so much better that I’d pay significantly more for them. Then again, I’m not the target audience and I don’t understand anything...
6/7/2026, 8:47 AM
by samamies
25
Inderes Novo Nordisk takes action to stop multiple misleading national GLP-1... A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of... Well,...
7/21/2026, 4:48 PM
by JNivala
21
https://www.marketwatch.com/story/the-wegovy-pill-is-still-dominating-the-glp-1-pill-market-f7add507?mod=home_lead Pill sales have gotten off to a nice start. Eli Lilly’s pill sales launched much more sluggishly.
6/8/2026, 6:44 AM
by Kryptoniitti
20
Manufacturing semaglutide is a demanding process, so as I understand it, its price will not drop to the level of aspirin anytime soon. Novo holds a competitive advantage in manufacturing processes and production machinery, allowing them to generate strong profits for a long time—...
6/7/2026, 4:08 PM
by Kari Kokkonen
13
Here is an article from SalkunRakentaja about Novo, a concise piece on Novo Nordisk that can be read in a few minutes. It shouldn’t contain major new information for those following the company closely, but it’s a good overview nonetheless. The market reaction has been twofold. In...
6/20/2026, 6:23 AM
by Sijoittaja-alokas
11
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8.
2026

Interim report Q2'26

4.11.
2026

Interim report Q3'26

Press release21.07.2026 klo 14.35

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

Novo Nordisk
Regulatory press release20.07.2026 klo 15.31

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release15.07.2026 klo 18.50

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release13.07.2026 klo 15.24

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release06.07.2026 klo 13.16

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release29.06.2026 klo 15.10

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release22.06.2026 klo 15.51

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release15.06.2026 klo 14.02

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release11.06.2026 klo 18.30

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk
Press release11.06.2026 klo 18.02

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk
Regulatory press release08.06.2026 klo 15.09

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release03.06.2026 klo 09.00

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk
Regulatory press release01.06.2026 klo 14.16

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release26.05.2026 klo 17.16

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release26.05.2026 klo 11.41

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Novo Nordisk
Regulatory press release22.05.2026 klo 20.30

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Novo Nordisk
Regulatory press release22.05.2026 klo 16.08

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

Novo Nordisk
Press release19.05.2026 klo 15.00

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk
Regulatory press release18.05.2026 klo 16.38

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release13.05.2026 klo 09.00

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Novo Nordisk